论文部分内容阅读
在过去的六个月中,美国的百白破(DTP)三联菌苗的制造和销售都发生了很大变化。现在三个商业性制造厂家已有两家(Wyeth和Connaught Inc)停止销售他们的菌苗产品。美国目前只有一家(Lederle)在市场上提供DTP菌苗。Lederle厂已扩大了它的生产量并增加了设备以满足目前的需要。对以往的产量和生产进度严格的监测表明,国家供应的菌苗是足够的,但最近由Lederle厂生产的DTP菌苗已不能满足市场
In the past six months, there has been a dramatic shift in the manufacture and sale of the DTP triad in the United States. Two commercial manufacturers now have two (Wyeth and Connaught Inc) to stop selling their vaccine products. Currently, only one (Lederle) U.S. provides DTP vaccine on the market. Lederle has expanded its production and added equipment to meet current needs. A rigorous monitoring of past production and production schedules shows that the national supply of bacterins is sufficient, but the DTP vaccine recently produced at the Lederle plant can no longer satisfy the market